Chinese firms chase 94% jump in private health insurance revenue

(Bloomberg) — Gaming firms, real-estate companies and drugmakers in China are chasing what they hope will be the country’s next hot commodity: private health insurance.

At least 29 publicly traded Chinese companies have announced plans to invest in commercial insurance businesses since 2015, according to a report from researcher VC Beat and corporate statements. The new ventures are focused partly, or entirely, on health insurance, an area where affluent Chinese families are ramping up spending.

The China Insurance Regulatory Commission, a government body, estimates that premium income for private health insurers jumped by 94 percent in the first seven months this year. That topped the last year’s already substantial 52 percent surge, fueled by policy incentives and China’s rising prevalence of chronic conditions like heart disease.

“The growth is sustainable because all the drivers will continue to be there, especially the demand for health-care services,” said Luo Ying, partner and managing director at consultancy Boston Consulting Group. In an August report, BCG and insurer Munich Re estimated that the market measured by premium income will more than quadruple from 240 billion yuan ($36 billion) last year to 1.1 trillion yuan by 2020.

Burdened by the rising cost of its vast public health system, China has for years sought to encourage private company entrants. Those efforts gained a substantial boost recently from a 31-city trial program, which provided an income tax exemption on insurance premium payments, albeit for only up to 2,400 yuan a year.

The emergence of private health insurance is a new trend and most people in China still rely on a government-backed scheme which doesn’t cover many costly drugs for diseases like cancer. Patients also face lengthy delays at public hospitals for care. Private health insurance accounted for only about 7 percent of personal health expenditure in China last year, according to BCG.

Rapid development

Companies venturing into health insurance range from drug manufacturer Kangmei Pharmaceutical Co. and physical check-up chain Meinian Onehealth Healthcare Holdings Co., to even property developer Suning Universal Co. and Dalian Zeus Entertainment Group Co., which develops online games.

Alibaba Health Information Technology Ltd., the health-care arm of billionaire Jack Ma’s Alibaba Group Holding Ltd., in April announced plans to form a joint venture with partners including China Taiping Insurance Holdings Co. for Internet health insurance-related operations in China. Due to government restrictions on foreign investments in health insurance, multinationals like Cigna Corp. and Allianz SE often operate through joint ventures with local partners in China.

Health-related companies often invest in insurance to provide a more complete range of services, while other firms might be seeking to diversify into a high-growth business, said Zhao Heng, founder of a local health-care consultancy called Latitude Health.

As China continues to urbanize and age, commercial health insurance has entered a state of rapid development and investing in a health insurer represents a step in Suning Universal’s transition toward the finance sector, the company said in an Aug. 25 statement.

Public hospitals

Getting an insurance license can also be difficult for many companies and another major risk is “a weak understanding of the market,” said Zhao. Unlike other insurers, health insurance companies often face high payment ratios and may not always be able to reap large profits even in developed markets, added Zhao.

China’s public hospitals remain heavily dependent on medicine sales for revenue. Therefore, doctors lack the incentive to control costs, a headache for commercial health insurance providers, according to Zhao.

The solution to the problem, BCG says, will be the rise of private hospitals in China. The number of private hospitals grew by 16 percent annually between 2005 and 2014, according to the consultancy’s calculations, while the number of public ones fell by 2 percent.

Policies that offer a one-off payment in case of specified major illnesses, such as when the customer is diagnosed with specific types of cancer, currently dominate China’s commercial health insurance market, and have contributed much of the growth in the past few years. However, Zhao estimates at least half of them were sold as add-ons to wealth management products. “In the long run this kind of growth is unsustainable because customers were buying WMPs, not health insurance.”

Implementation of policy incentives such as the income tax benefit also face challenges, said BCG’s Luo. “But going forward, we believe the policies will continue to improve and more such policies will be issued.”